Viatris Inc. (VTRS) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $16.54: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality.
Viatris is a global pharma company supplying generics, branded, and innovative medicines to ~1 billion patients annually across 165+ countries through four segments (Developed Markets, Emerging Markets, JANZ, Greater China), with 2025 total revenues of $14.30 billion. Following... Read more
Sell if holding. Engine safety override at $16.54: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Score 5.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Viatris Inc.
Material events (past 30 days)
- May 4, 2026 MEDIUM Item 5.02: CFO Theodora Mistras resigned effective May 8, 2026 to pursue another opportunity. Paul Campbell (current CAO/Controller) appointed interim CFO effective May 8, 2026 while Board searches for permanent CFO. No disagreement cited.
Latest news
- Viatris' New Drug Application For Moderate-To-Severe Acute Pain Treatment Receives FDA's Acceptance For Review — benzinga May 18, 2026 positive
- RFK Jr. Wants Fewer Americans On Antidepressants — Here's Why The Debate Is Exploding — benzinga May 8, 2026 neutral
- JP Morgan Maintains Neutral on Viatris, Raises Price Target to $18 — benzinga May 8, 2026 neutral
- Truist Securities Maintains Buy on Viatris, Raises Price Target to $20 — benzinga May 8, 2026 positive
- 'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive — benzinga May 8, 2026 neutral
Generated 2026-05-20T20:21:22Z.
Thesis
Key Metrics
Quality Signals
Material Events(8-K, last 90d)
- 2026-05-04Item 5.02MEDIUMCFO Theodora Mistras resigned effective May 8, 2026 to pursue another opportunity. Paul Campbell (current CAO/Controller) appointed interim CFO effective May 8, 2026 while Board searches for permanent CFO. No disagreement cited.SEC filing →
- 2026-02-26Item 2.05MEDIUMViatris announced EWSR restructuring: global workforce reduction of up to ~10%, total pre-tax charges of $700M-$850M expected over ~3 years, targeting $600-700M in savings. Includes headcount cuts, facility closures, and supply chain optimization.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Unprofitable operations — net margin -2.0%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.54: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Prior stop was $15.38. Score 5.3/10, moderate confidence.
Take-profit target: $17.18 (+3.9% upside). Prior stop was $15.38. Stop-loss: $15.38.
Target reached (-8.0% upside); Quality below floor (3.4 < 4.0); Value-trap signals (2/5): Margin compression (op margin 2.8%), Negative free cash flow.
Viatris Inc. trades at a P/E of N/A (forward 6.2). TrendMatrix value score: 8.1/10. Verdict: Sell.
18 analysts cover VTRS with a consensus score of 3.8/5. Average price target: $18.
What does Viatris Inc. do?Viatris is a global pharma company supplying generics, branded, and innovative medicines to ~1 billion patients...
Viatris is a global pharma company supplying generics, branded, and innovative medicines to ~1 billion patients annually across 165+ countries through four segments (Developed Markets, Emerging Markets, JANZ, Greater China), with 2025 total revenues of $14.30 billion. Following its 2025 enterprise-wide strategic review, it is executing a restructuring targeting $600-700M in savings and a ~10% global headcount reduction.